Sumitomo Pharma
Sumitomo Pharma Co Ltd is a Japanese pharmaceutical company developing prescription medicines in psychiatry, neurology, and oncology. The company researches, manufactures, and markets pharmaceutical products for central nervous system disorders, cancer, regenerative medicine, and rare diseases. Main revenue drivers stem from global sales of ethical pharmaceutical products, including treatments for schizophrenia, prostate cancer, and Parkinson's disease. Sumitomo Pharma serves hospitals, medical practitioners, prescription pharmacies, and patients in Japan, North America, China, and Europe. The company maintains an established market position as a research-driven pharmaceutical enterprise in Japan. Headquartered in Osaka, Japan, Sumitomo Pharma Co Ltd is listed on the Tokyo Stock Exchange.
8 of the funds FundTelligence covers report a position in Sumitomo Pharma.
- Legal name
- Sumitomo Pharma Co Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 8
Funds holding Sumitomo Pharma
- Handelsbanken Japan Tema — Handelsbanken · 0.81 % (full portfolio disclosed, October 2026)
- T. Rowe Price Japanese Equity Fund — T. Rowe Price · 0.51 % (full portfolio disclosed, September 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.11 % (full portfolio disclosed, September 2026)
- Handelsbanken Utviklede Markeder Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Nordea Internationale aktier — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)